Details
Stereochemistry | RACEMIC |
Molecular Formula | C25H37NO4.C11H8O3 |
Molecular Weight | 603.745 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC=C2C=CC=CC2=C1O.OCC3=CC(=CC=C3O)C(O)CNCCCCCCOCCCCC4=CC=CC=C4
InChI
InChIKey=XTZNCVSCVHTPAI-UHFFFAOYSA-N
InChI=1S/C25H37NO4.C11H8O3/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21;12-10-8-4-2-1-3-7(8)5-6-9(10)11(13)14/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2;1-6,12H,(H,13,14)
Molecular Formula | C11H8O3 |
Molecular Weight | 188.1794 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C25H37NO4 |
Molecular Weight | 415.5656 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/mtm/salmeterol-inhalation.html
http://www.rxlist.com/serevent-diskus-drug.htm
http://www.wikidoc.org/index.php/Salmeterol
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/mtm/salmeterol-inhalation.html
http://www.rxlist.com/serevent-diskus-drug.htm
http://www.wikidoc.org/index.php/Salmeterol
Salmeterol is a long-acting beta2-adrenergic agonist. Although beta2-adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-adrenoceptors are the predominant receptors in the heart, there are also beta2-adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these is not yet established, but they raise the possibility that even highly selective beta2-agonists may have cardiac effects. It is FDA approved for the treatment of asthma, prevention of exercise-induced bronchospasm, maintenance treatment of chronic obstructive pulmonary disease. Common adverse reactions include musculoskeletal pain, headache, influenza, nasal/sinus congestion, pharyngitis, rhinitis, tracheitis/bronchitis, cough, throat irritation, viral respiratory infection. Salmeterol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of salmeterol on the vascular system may be potentiated by these agents. Coadministration of salmeterol and ketoconazole was associated with more frequent increases in QTc duration compared with salmeterol and placebo administration.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7905380
Curator's Comment: Known to be CNS penetrant in rat. Human data not available.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL210 |
1.5 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | SEREVENT Approved UseADVAIR DISKUS is a combination product containing a corticosteroid and a LABA indicated for: Treatment of asthma in patients aged 4 years and older. (1.1) Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). (1.2) Important limitation: Not indicated for the relief of acute bronchospasm. (1.1, 1.2) 1.1 Treatment of Asthma ADVAIR DISKUS is indicated for the treatment of asthma in patients aged 4 years and older. Long-acting beta2-adrenergic agonists (LABAs), such as salmeterol, one of the active ingredients in ADVAIR DISKUS, increase the risk of asthma-related death. Available data from controlled clinical trials suggest that LABAs increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see Warnings and Precautions (5.1) Launch Date7.6031997E11 |
|||
Palliative | SEREVENT Approved UseADVAIR DISKUS is a combination product containing a corticosteroid and a LABA indicated for: Treatment of asthma in patients aged 4 years and older. (1.1) Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). (1.2) Important limitation: Not indicated for the relief of acute bronchospasm. (1.1, 1.2) 1.1 Treatment of Asthma ADVAIR DISKUS is indicated for the treatment of asthma in patients aged 4 years and older. Long-acting beta2-adrenergic agonists (LABAs), such as salmeterol, one of the active ingredients in ADVAIR DISKUS, increase the risk of asthma-related death. Available data from controlled clinical trials suggest that LABAs increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see Warnings and Precautions (5.1) Launch Date7.6031997E11 |
|||
Preventing | SEREVENT Approved UseADVAIR DISKUS is a combination product containing a corticosteroid and a LABA indicated for: Treatment of asthma in patients aged 4 years and older. (1.1) Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). (1.2) Important limitation: Not indicated for the relief of acute bronchospasm. (1.1, 1.2) 1.1 Treatment of Asthma ADVAIR DISKUS is indicated for the treatment of asthma in patients aged 4 years and older. Long-acting beta2-adrenergic agonists (LABAs), such as salmeterol, one of the active ingredients in ADVAIR DISKUS, increase the risk of asthma-related death. Available data from controlled clinical trials suggest that LABAs increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see Warnings and Precautions (5.1) Launch Date7.6031997E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
319 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29493402/ |
50 μg single, oral dose: 50 μg route of administration: Oral experiment type: SINGLE co-administered: FLUTICASONE PROPIONATE |
SALMETEROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
167 pg/mL |
50 μg 2 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
SALMETEROL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
464 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29493402/ |
50 μg single, oral dose: 50 μg route of administration: Oral experiment type: SINGLE co-administered: FLUTICASONE PROPIONATE |
SALMETEROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10.72 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29493402/ |
50 μg single, oral dose: 50 μg route of administration: Oral experiment type: SINGLE co-administered: FLUTICASONE PROPIONATE |
SALMETEROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
5.5 h |
50 μg 2 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
SALMETEROL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4% |
50 μg 2 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered: |
SALMETEROL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
84 ug 2 times / day multiple, respiratory Dose: 84 ug, 2 times / day Route: respiratory Route: multiple Dose: 84 ug, 2 times / day Sources: |
unhealthy, 30 n = 31 Health Status: unhealthy Condition: asthma Age Group: 30 Sex: M+F Population Size: 31 Sources: |
Other AEs: Headache, Dizziness... Other AEs: Headache (5 patients) Sources: Dizziness (2 patients) Tremor (5 patients) Palpitations (1 patient) Muscle cramps (1 patient) |
400 ug single, respiratory Dose: 400 ug Route: respiratory Route: single Dose: 400 ug Sources: |
healthy, 34.3 n = 10 Health Status: healthy Age Group: 34.3 Sex: M Population Size: 10 Sources: |
Other AEs: Headache, Tremor... Other AEs: Headache (5 patients) Sources: Tremor (5 patients) Palpitations (3 patients) |
50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy, 4-11 n = 211 Health Status: unhealthy Condition: asthma Age Group: 4-11 Population Size: 211 Sources: |
Other AEs: Ear disorder, Pharyngitis... Other AEs: Ear disorder (4%) Sources: Pharyngitis (6%) Headache (17%) Asthma (4%) Skin rash (4%) Urticaria (3%) |
50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy, >12 n = 149 Health Status: unhealthy Condition: asthma Age Group: >12 Population Size: 149 Sources: |
Other AEs: Nasal sinus congestion, Rhinitis... Other AEs: Nasal sinus congestion (9%) Sources: Rhinitis (5%) Headache (13%) Asthma (3%) Tracheobronchitis (7%) Influenza (5%) |
50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy n = 341 Health Status: unhealthy Condition: COPD Population Size: 341 Sources: |
Other AEs: Hypertension, Throat irritation... Other AEs: Hypertension (4%) Sources: Throat irritation (7%) Congestion nasal (4%) Sinusitis (4%) Ear disorder (3%) Nausea and vomiting (3%) Cough (5%) Rhinitis (4%) Respiratory tract infection viral (5%) Musculoskeletal pain (12%) Muscle cramps (3%) Headache (14%) Dizziness (4%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Muscle cramps | 1 patient | 84 ug 2 times / day multiple, respiratory Dose: 84 ug, 2 times / day Route: respiratory Route: multiple Dose: 84 ug, 2 times / day Sources: |
unhealthy, 30 n = 31 Health Status: unhealthy Condition: asthma Age Group: 30 Sex: M+F Population Size: 31 Sources: |
Palpitations | 1 patient | 84 ug 2 times / day multiple, respiratory Dose: 84 ug, 2 times / day Route: respiratory Route: multiple Dose: 84 ug, 2 times / day Sources: |
unhealthy, 30 n = 31 Health Status: unhealthy Condition: asthma Age Group: 30 Sex: M+F Population Size: 31 Sources: |
Dizziness | 2 patients | 84 ug 2 times / day multiple, respiratory Dose: 84 ug, 2 times / day Route: respiratory Route: multiple Dose: 84 ug, 2 times / day Sources: |
unhealthy, 30 n = 31 Health Status: unhealthy Condition: asthma Age Group: 30 Sex: M+F Population Size: 31 Sources: |
Headache | 5 patients | 84 ug 2 times / day multiple, respiratory Dose: 84 ug, 2 times / day Route: respiratory Route: multiple Dose: 84 ug, 2 times / day Sources: |
unhealthy, 30 n = 31 Health Status: unhealthy Condition: asthma Age Group: 30 Sex: M+F Population Size: 31 Sources: |
Tremor | 5 patients | 84 ug 2 times / day multiple, respiratory Dose: 84 ug, 2 times / day Route: respiratory Route: multiple Dose: 84 ug, 2 times / day Sources: |
unhealthy, 30 n = 31 Health Status: unhealthy Condition: asthma Age Group: 30 Sex: M+F Population Size: 31 Sources: |
Palpitations | 3 patients | 400 ug single, respiratory Dose: 400 ug Route: respiratory Route: single Dose: 400 ug Sources: |
healthy, 34.3 n = 10 Health Status: healthy Age Group: 34.3 Sex: M Population Size: 10 Sources: |
Headache | 5 patients | 400 ug single, respiratory Dose: 400 ug Route: respiratory Route: single Dose: 400 ug Sources: |
healthy, 34.3 n = 10 Health Status: healthy Age Group: 34.3 Sex: M Population Size: 10 Sources: |
Tremor | 5 patients | 400 ug single, respiratory Dose: 400 ug Route: respiratory Route: single Dose: 400 ug Sources: |
healthy, 34.3 n = 10 Health Status: healthy Age Group: 34.3 Sex: M Population Size: 10 Sources: |
Headache | 17% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy, 4-11 n = 211 Health Status: unhealthy Condition: asthma Age Group: 4-11 Population Size: 211 Sources: |
Urticaria | 3% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy, 4-11 n = 211 Health Status: unhealthy Condition: asthma Age Group: 4-11 Population Size: 211 Sources: |
Asthma | 4% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy, 4-11 n = 211 Health Status: unhealthy Condition: asthma Age Group: 4-11 Population Size: 211 Sources: |
Ear disorder | 4% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy, 4-11 n = 211 Health Status: unhealthy Condition: asthma Age Group: 4-11 Population Size: 211 Sources: |
Skin rash | 4% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy, 4-11 n = 211 Health Status: unhealthy Condition: asthma Age Group: 4-11 Population Size: 211 Sources: |
Pharyngitis | 6% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy, 4-11 n = 211 Health Status: unhealthy Condition: asthma Age Group: 4-11 Population Size: 211 Sources: |
Headache | 13% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy, >12 n = 149 Health Status: unhealthy Condition: asthma Age Group: >12 Population Size: 149 Sources: |
Asthma | 3% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy, >12 n = 149 Health Status: unhealthy Condition: asthma Age Group: >12 Population Size: 149 Sources: |
Influenza | 5% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy, >12 n = 149 Health Status: unhealthy Condition: asthma Age Group: >12 Population Size: 149 Sources: |
Rhinitis | 5% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy, >12 n = 149 Health Status: unhealthy Condition: asthma Age Group: >12 Population Size: 149 Sources: |
Tracheobronchitis | 7% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy, >12 n = 149 Health Status: unhealthy Condition: asthma Age Group: >12 Population Size: 149 Sources: |
Nasal sinus congestion | 9% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy, >12 n = 149 Health Status: unhealthy Condition: asthma Age Group: >12 Population Size: 149 Sources: |
Musculoskeletal pain | 12% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy n = 341 Health Status: unhealthy Condition: COPD Population Size: 341 Sources: |
Headache | 14% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy n = 341 Health Status: unhealthy Condition: COPD Population Size: 341 Sources: |
Ear disorder | 3% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy n = 341 Health Status: unhealthy Condition: COPD Population Size: 341 Sources: |
Muscle cramps | 3% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy n = 341 Health Status: unhealthy Condition: COPD Population Size: 341 Sources: |
Nausea and vomiting | 3% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy n = 341 Health Status: unhealthy Condition: COPD Population Size: 341 Sources: |
Congestion nasal | 4% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy n = 341 Health Status: unhealthy Condition: COPD Population Size: 341 Sources: |
Dizziness | 4% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy n = 341 Health Status: unhealthy Condition: COPD Population Size: 341 Sources: |
Hypertension | 4% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy n = 341 Health Status: unhealthy Condition: COPD Population Size: 341 Sources: |
Rhinitis | 4% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy n = 341 Health Status: unhealthy Condition: COPD Population Size: 341 Sources: |
Sinusitis | 4% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy n = 341 Health Status: unhealthy Condition: COPD Population Size: 341 Sources: |
Cough | 5% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy n = 341 Health Status: unhealthy Condition: COPD Population Size: 341 Sources: |
Respiratory tract infection viral | 5% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy n = 341 Health Status: unhealthy Condition: COPD Population Size: 341 Sources: |
Throat irritation | 7% | 50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: |
unhealthy n = 341 Health Status: unhealthy Condition: COPD Population Size: 341 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
weak | ||||
weak | ||||
yes [Activation 25.1189 uM] | ||||
yes [IC50 1.87 uM] | ||||
yes [IC50 47.8 uM] | ||||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
unlikely | ||||
yes | ||||
yes | ||||
yes | yes (co-administration study) Comment: Coadministration of inhaled Salmetrol and oral ketoconazole (strong CYP3A4 inhibitor) for 7 days increased Salmetrol AUC by 16-fold and Cmax by 1.4-fold. Coadministration of Erythromycin (moderate CYP3A4 inhibitor) increased inhaled Salmeterol Cmax,ss by 40% (3.6-beat/min in heart rate, 5.8-msec increase in QTc interval). Page: 13-14, 21-22 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease. | 1991 Nov |
|
[Salmeterol-induced enuresis in children]. | 1996 May 22 |
|
Salmeterol inhibits the allergen-induced mononuclear cell proliferation and downregulates GM-CSF release and HLA-DR expression by monocytes. | 1997 |
|
Salmeterol versus theophylline in the treatment of asthma. | 1997 May |
|
Onset of bronchodilation and finger tremor induced by salmeterol and salbutamol in asthmatic patients. | 1998 May-Jun |
|
Effects of a range of beta2 adrenoceptor agonists on changes in intracellular cyclic AMP and on cyclic AMP driven gene expression in cultured human airway smooth muscle cells. | 1999 Oct |
|
Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. | 2000 Aug |
|
Comparative effects of long-acting beta2-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma. | 2000 Sep |
|
Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease. | 2001 |
|
Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma. | 2002 Jul |
|
Effects of low dose fluticasone/salmeterol combination on surrogate inflammatory markers in moderate persistent asthma. | 2003 Jul |
|
Stimulation of beta 2-adrenergic receptor increases cystic fibrosis transmembrane conductance regulator expression in human airway epithelial cells through a cAMP/protein kinase A-independent pathway. | 2003 May 9 |
|
Characterization of agonist stimulation of cAMP-dependent protein kinase and G protein-coupled receptor kinase phosphorylation of the beta2-adrenergic receptor using phosphoserine-specific antibodies. | 2004 Jan |
|
Long-acting beta2-adrenergic formoterol and salmeterol induce the apoptosis of B-chronic lymphocytic leukaemia cells. | 2004 Jan |
|
Examination of 209 drugs for inhibition of cytochrome P450 2C8. | 2005 Jan |
|
Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. | 2005 Sep 15 |
|
Inhaled corticosteroids and long-acting beta 2-agonists in treatment of patients with chronic bronchiolitis following exposure to sulfur mustard. | 2007 Aug |
|
The effect of corticosteroids on the disposal of long-acting beta2-agonists by airway smooth muscle cells. | 2007 Nov |
|
Budesonide prevents cytokine-induced decrease of the relaxant responses to formoterol and terbutaline, but not to salmeterol, in mouse trachea. | 2010 Apr |
|
Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study. | 2012 Jul 1 |
Sample Use Guides
Asthma and Chronic Obstructive Pulmonary Disease: the usual dosage for adults and children 4 years of age and older is 1 inhalation (50 mcg) twice daily (morning and evening, approximately 12 hours apart).
Exercise-Induced Bronchospasm: One inhalation of SEREVENT DISKUS at least 30 minutes before exercise.
Route of Administration:
Respiratory
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11510784
Since fibroblasts express beta2-adrenoreceptors, the effects of different concentrations (0.1-100 nM) of salmeterol on lung fibroblast proliferation and adhesion molecule expression were evaluated. A significant downregulation of ICAM-1 or H-CAM expression was demonstrated in the presence of Salmeterol, at all concentrations tested (0.1-100 nM; p<0.01).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 19:57:22 UTC 2022
by
admin
on
Fri Dec 16 19:57:22 UTC 2022
|
Record UNII |
6EW8Q962A5
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C319
Created by
admin on Fri Dec 16 19:57:22 UTC 2022 , Edited by admin on Fri Dec 16 19:57:22 UTC 2022
|
||
|
FDA ORPHAN DRUG |
273208
Created by
admin on Fri Dec 16 19:57:22 UTC 2022 , Edited by admin on Fri Dec 16 19:57:22 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB04314MIG
Created by
admin on Fri Dec 16 19:57:22 UTC 2022 , Edited by admin on Fri Dec 16 19:57:22 UTC 2022
|
PRIMARY | |||
|
M9745
Created by
admin on Fri Dec 16 19:57:22 UTC 2022 , Edited by admin on Fri Dec 16 19:57:22 UTC 2022
|
PRIMARY | Merck Index | ||
|
BB-30
Created by
admin on Fri Dec 16 19:57:22 UTC 2022 , Edited by admin on Fri Dec 16 19:57:22 UTC 2022
|
PRIMARY | |||
|
6EW8Q962A5
Created by
admin on Fri Dec 16 19:57:22 UTC 2022 , Edited by admin on Fri Dec 16 19:57:22 UTC 2022
|
PRIMARY | |||
|
DBSALT001372
Created by
admin on Fri Dec 16 19:57:22 UTC 2022 , Edited by admin on Fri Dec 16 19:57:22 UTC 2022
|
PRIMARY | |||
|
C61935
Created by
admin on Fri Dec 16 19:57:22 UTC 2022 , Edited by admin on Fri Dec 16 19:57:22 UTC 2022
|
PRIMARY | |||
|
56801
Created by
admin on Fri Dec 16 19:57:22 UTC 2022 , Edited by admin on Fri Dec 16 19:57:22 UTC 2022
|
PRIMARY | |||
|
94749-08-3
Created by
admin on Fri Dec 16 19:57:22 UTC 2022 , Edited by admin on Fri Dec 16 19:57:22 UTC 2022
|
PRIMARY | |||
|
72616
Created by
admin on Fri Dec 16 19:57:22 UTC 2022 , Edited by admin on Fri Dec 16 19:57:22 UTC 2022
|
PRIMARY | RxNorm | ||
|
1609603
Created by
admin on Fri Dec 16 19:57:22 UTC 2022 , Edited by admin on Fri Dec 16 19:57:22 UTC 2022
|
PRIMARY | |||
|
DTXSID1045798
Created by
admin on Fri Dec 16 19:57:22 UTC 2022 , Edited by admin on Fri Dec 16 19:57:22 UTC 2022
|
PRIMARY | |||
|
CHEMBL1263
Created by
admin on Fri Dec 16 19:57:22 UTC 2022 , Edited by admin on Fri Dec 16 19:57:22 UTC 2022
|
PRIMARY | |||
|
6EW8Q962A5
Created by
admin on Fri Dec 16 19:57:22 UTC 2022 , Edited by admin on Fri Dec 16 19:57:22 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
EP
|
||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |